Sammenlignet med patienter, der ikke udviklede antistoffer, er der ikke blevet observeret nogen forbindelse mellem forekomsten af anti- panitumumab- antistoffer og farmakokinetik, effekt og sikkerhed.
Compared with patients who did not develop antibodies, no relationship between the presence of anti-panitumumab antibodies and pharmacokinetics, efficacy and safety has been observed.